Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

Study looks at blood type and risk of cognitive impairment

People with blood type AB may be more likely to develop memory loss in later years than people with other blood types, according to a study published in the September 10, 2014, online issue of Neurology®, the medical journal of the American Academy of Neurology.

11 Sep 2014

People with diabetes may have six-fold higher risk of developing heart failure

People with diabetes who appear otherwise healthy may have a six-fold higher risk of developing heart failure regardless of their cholesterol levels, new Johns Hopkins Bloomberg School of Public Health research suggests.

11 Sep 2014

Weak spot in complex life cycle of malaria could prevent spread of deadly disease

A new study has revealed a weak spot in the complex life cycle of malaria, which could be exploited to prevent the spread of the deadly disease.

10 Sep 2014

5-minute walks can reverse harm caused to leg arteries from prolonged sitting

An Indiana University study has found that three easy -- one could even say slow -- 5-minute walks can reverse harm caused to leg arteries during three hours of prolonged sitting.

9 Sep 2014

Regular consumption of mango by obese adults may lower blood sugar levels

Research published in the journal Nutrition and Metabolic Insights found that regular consumption of mango by obese adults may lower blood sugar levels and does not negatively impact body weight.

9 Sep 2014

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries.

8 Sep 2014

Endo International introduces topical testosterone gel, FORTESTA Gel

Endo International plc announced today that it has introduced the first and only generic 2% topical testosterone gel, an authorized generic of FORTESTA® Gel (testosterone gel) CIII.

8 Sep 2014

Investigators make thought-provoking discovery about type of cholesterol believed to be "bad guy"

A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.

5 Sep 2014

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer.

5 Sep 2014

Doctor receives international patents for therapeutic process to remove excess galectin-3

Isaac Eliaz, MD, MS, LAc has been awarded a USA patent as well as additional international patents for a therapeutic process that allows for the removal of excess galectin-3 from the circulatory system using plasmapheresis.

4 Sep 2014

Researchers uncover intriguing link between heart attacks and protein

A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact on cholesterol.

4 Sep 2014

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain.

3 Sep 2014

Alirocumab drug significantly improves cholesterol levels compared to ezetimibe

The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014.

1 Sep 2014

New polypill increases adherence to treatment following myocardial infarction

A new polypill increases adherence to treatment following a myocardial infarction (MI), according to results from the FOCUS Study presented for the first time at ESC Congress 2014 today by principal investigator Dr Valentin Fuster, director of Mount Sinai Heart in New York, US.

1 Sep 2014

'Good' cholesterol turns 'bad' by sugar-derived substance

Scientists at the University of Warwick have discovered that 'good' cholesterol is turned 'bad' by a sugar-derived substance.

1 Sep 2014

BIOCRATES launches first-ever bile acids kit based on targeted metabolite quantitation

Austrian BIOCRATES Life Sciences AG, internationally renowned developer and marketer of innovative targeted metabolomics solutions, further expands its range of metabolomics-based kits with the addition of its assay for the determination of endogenous bile acids, allowing a panel of up to 19 analytes to be simultaneously quantitated from a single 10 µL sample of human or mouse plasma.

1 Sep 2014

Combination of moderate wine drinking plus regular exercise protects against CVD

Wine only protects against cardiovascular disease (CVD) in people who exercise, according to results from the In Vino Veritas (IVV) study presented at ESC Congress today by Professor Milos Taborsky from the Czech Republic.

1 Sep 2014

Amgen seeks FDA approval for evolocumab to treat patients with high cholesterol

Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for evolocumab seeking approval for the treatment of high cholesterol.

28 Aug 2014

Risk-based treatment approach should be considered for patients with hypertension

Blood pressure-lowering treatment should target patients at greatest cardiovascular risk and not just those with the highest baseline levels, suggest findings of a meta-analysis.

28 Aug 2014

Merz Pharmaceuticals launches new CAIDE Dementia Risk App

The CAIDE Dementia Risk App from Merz Pharmaceuticals is available free of charge for people from 40 to 65 to calculate their individual risk for getting dementia within the next two decades. Using a traffic light color scheme, the App can also help physicians discuss preventive measures with patients at risk.

28 Aug 2014